Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam vs midazolam for continuous ICU sedation in mechanically ventilated patients
ChiCTR2300071553Phase 4Not yet recruiting
- Sponsor
- Neijiang City Central District People's Hospital
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of remimazolam (2 arms), sponsored by Neijiang City Central District People's Hospital. Primary endpoint: RASS sedation score. Planned start May 2023; status: not yet recruiting.
02
Drugs
remimazolam
Beyond the preview
Go deeper on ChiCTR2300071553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071553.